Please use this identifier to cite or link to this item:
|Title:||Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells|
|Authors:||Zhao, J. |
|Citation:||Zhao, J., Lu, Y., Shen, H.-M. (2012-01-01). Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells. Cancer Letters 314 (1) : 8-23. ScholarBank@NUS Repository. https://doi.org/10.1016/j.canlet.2011.09.040|
|Abstract:||Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has been intensively studied as a cancer therapeutic agent due to its unique ability to induce apoptosis in malignant cells but not in normal cells. However, as more human cancer cells are reported to be resistant to TRAIL treatment, it is important to develop new therapeutic strategies to overcome this resistance. p53 is an important tumor suppressor that is widely involved in cellular responses to various stresses. In this mini-review, we aim to provide an overview of the intricate relationship between p53 and the TRAIL-mediated apoptosis pathway, and to summarize the current approaches of targeting p53 as a therapeutic strategy to sensitize TRAIL-induced apoptosis in human cancer cells. Although in some cases TRAIL kills cancer cells in a p53-independent manner, it is believed that in cancers with wild-type and functional p53, targeting p53 may be an important strategy for overcoming TRAIL-resistance in cancer therapy. © 2011 Elsevier Ireland Ltd.|
|Source Title:||Cancer Letters|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 19, 2018
WEB OF SCIENCETM
checked on Jun 11, 2018
checked on Jun 8, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.